Abstract
Analyzing anatomic shapes of tissues and organs is pivotal for accurate disease diagnostics and clinical decision-making. One prominent disease that depends on anatomic shape analysis is osteoarthritis, which affects 30 million Americans. To advance osteoarthritis diagnostics and prognostics, we introduce ShapeMed-Knee, a 3D shape dataset with 9,376 high-resolution, medicalimaging-based 3D shapes of both femur bone and cartilage. Besides data, ShapeMed-Knee includes two benchmarks for assessing reconstruction accuracy and five clinical prediction tasks that assess the utility of learned shape representations. Leveraging ShapeMed-Knee, we develop and evaluate a novel hybrid explicit-implicit neural shape model which achieves up to 40% better reconstruction accuracy than a statistical shape model and two implicit neural shape models. Our hybrid models achieve state-of-the-art performance for preserving cartilage biomarkers (root mean squared error ≤ 0.05 vs. ≤ 0.07, 0.10, and 0.14). Our models are also the first to successfully predict localized structural features of osteoarthritis, outperforming shape models and convolutional neural networks applied to raw magnetic resonance images and segmentations (e.g., osteophyte size and localization 63% accuracy vs. 49-61%). The ShapeMed-Knee dataset provides medical evaluations to reconstruct multiple anatomic surfaces and embed meaningful disease-specific information. ShapeMed-Knee reduces barriers to applying 3D modeling in medicine, and our benchmarks highlight that advancements in 3D modeling can enhance the diagnosis and risk stratification for complex diseases. The dataset, code, and benchmarks are freely accessible.
Competing Interest Statement
AAG is a shareholder of NeuralSeg Ltd., and GeminiOV.
Funding Statement
This work was supported in part by the National Institutes of Health R01 AR077604, R01 EB002524, R01 AR079431, P41 EB027060, the Wu Tsai Human Performance Alliance, and a CIHR Postdoctoral Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data were acquired from the Osteoarthritis Initiative (OAI). https://nda.nih.gov/oai
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
(email: aagatti{at}stanford.edu)
This work was supported in part by the National Institutes of Health R01 AR077604, R01 EB002524, R01 AR079431, P41 EB027060, the Wu Tsai Human Performance Alliance, and a CIHR Postdoctoral Fellowship.
We have updated the manuscript to include additional ablation analyses and to improve clarity.
Data Availability
All data produced are available online at https://huggingface.co/datasets/aagatti/ShapeMedKnee